Avapritinib
- Generic Name
- Avapritinib
- Brand Names
- Ayvakit, Ayvakyt
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27FN10
- CAS Number
- 1703793-34-3
- Unique Ingredient Identifier
- 513P80B4YJ
- Background
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis. It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares...
- Indication
Avapritinib is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
...
- Associated Conditions
- Advanced Systemic Mastocytosis (AdvSM), Aggressive Systemic Mastocytosis, Indolent Systemic Mastocytosis, Mast Cell Leukemia (MCL), Metastatic Gastrointestinal Stromal Tumor (GIST), Systemic Mastocytosis With an Associated Hematological Neoplasm, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors.
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 455
- Registration Number
- NCT04116541
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
- Conditions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Blueprint Medicines Corporation
- Registration Number
- NCT03862885
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
- Conditions
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 251
- Registration Number
- NCT03731260
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇩🇪University Clinic Hamburg Eppendorf, University Cancer Center Hamburg (UCCH), Hamburg, Germany
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 103
- Registration Number
- NCT03580655
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 476
- Registration Number
- NCT03465722
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Northwestern Medicine, Chicago, Illinois, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 86
- Registration Number
- NCT02561988
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇺🇸Stanford Cancer Institute, Stanford, California, United States
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT02508532
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
🇩🇪University of Duisburg-Essen, Essen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.